Lupin is currently trading at Rs. 1152.00, up by 35.25 points or 3.16% from its previous closing of Rs. 1116.75 on the BSE.
The scrip opened at Rs. 1119.00 and has touched a high and low of Rs. 1156.00 and Rs. 1119.00 respectively. So far 483682 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 1750.00 on 29-Jul-2016 and a 52 week low of Rs. 1036.80 on 05-Jul-2017.
Last one week high and low of the scrip stood at Rs. 1156.00 and Rs. 1036.80 respectively. The current market cap of the company is Rs. 52081.51 crore.
The promoters holding in the company stood at 46.70%, while Institutions and Non-Institutions held 40.66% and 12.63% respectively.
Lupin has received final approval for its Flucytosine Capsules USP, 250 mg and 500 mg from the United States Food and Drug Administration (USFDA) to market a generic version of Valeant Pharmaceuticals International Inc’s Ancobon Capsules, 250 mg and 500 mg. Ancobon Capsules had US sales of $46.6 million, as per IMS MAT March 2017.
Lupin’s Flucytosine Capsules USP, 250 mg and 500 mg are AB rated generic equivalent of Valeant Pharmaceuticals International Inc’s Ancobon Capsules, 250 mg and 500 mg. Flucytosine Capsules USP, 250 mg and 500 mg are indicated for the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus.
Lupin is an innovation led transnational pharmaceutical company developing and delivering a wide range of branded & generic formulations, biotechnology products and APIs globally.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1847.30 |
| Dr. Reddys Lab | 1293.25 |
| Cipla | 1347.70 |
| Zydus Lifesciences | 938.90 |
| Lupin | 2377.90 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: